RV41 Stock Overview
Operates as a biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.68 |
| 52 Week High | US$10.40 |
| 52 Week Low | US$3.68 |
| Beta | 0.27 |
| 11 Month Change | -11.96% |
| 3 Month Change | -26.40% |
| 1 Year Change | -51.26% |
| 33 Year Change | -56.71% |
| 5 Year Change | -32.48% |
| Change since IPO | -95.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| RV41 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.6% | -0.02% | -1.5% |
| 1Y | -51.3% | -17.7% | 7.9% |
Return vs Industry: RV41 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: RV41 underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| RV41 volatility | |
|---|---|
| RV41 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RV41's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RV41's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| RV41 fundamental statistics | |
|---|---|
| Market cap | €103.97m |
| Earnings (TTM) | -€1.08m |
| Revenue (TTM) | €46.88m |
2.2x
P/S Ratio-97.7x
P/E RatioIs RV41 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RV41 income statement (TTM) | |
|---|---|
| Revenue | US$49.35m |
| Cost of Revenue | US$3.20m |
| Gross Profit | US$46.15m |
| Other Expenses | US$47.28m |
| Earnings | -US$1.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 93.52% |
| Net Profit Margin | -2.30% |
| Debt/Equity Ratio | -620.7% |
How did RV41 perform over the long term?
See historical performance and comparison